Ultima Genomics is developing a high-throughput, low-cost DNA sequencing platform designed to sequence a whole human genome for around $100. The company's open silicon wafer substrate delivers billions of reads at low cost, combined with efficient sequencing chemistry and machine learning. Founded in 2016, Ultima has nearly 400 employees and is preparing for the commercial launch of its first product, the UG 100 sequencer, in early 2024 following an early access program.
Ultima Genomics was founded by Gilad Almogy, who brings a background in applied physics and experience scaling semiconductor technologies to drive down costs. The leadership team also includes genomics industry veterans from Illumina, Foundation Medicine, Genapsys and other companies. Ultima has raised around $600 million from top investors including General Atlantic, Andreessen Horowitz, D1 Capital, Khosla Ventures, and Lightspeed.
By making high-volume, low-cost whole genome sequencing a reality, Ultima aims to open new possibilities in genomics research and precision medicine. Employees have the opportunity to work on a cutting-edge genomic sequencing platform alongside an experienced cross-disciplinary team. However, Ultima will need to demonstrate that its platform can deliver the cost, speed, accuracy and scale advantages it promises as it seeks to challenge entrenched competitors like Illumina.
2016
Founded
250-500
Employees
Series E
Stage
$3B-$10B
Latest Valuation
$400-700M
Total Funding
May 31 2022
Last Fundraise
Why is the rating
Top Previous Employers

Genapsys

Illumina

Life Technologies

Thermo Fisher Scientific

University of California, Davis
Investors

Andreessen Horowitz
Coinbase, Slack, Flexport

Founders Fund
Facebook, SpaceX, Affirm

Khosla Ventures
OpenAI, Square, Oscar